Presenter Status
Resident/Psychology Intern
Abstract Type
Research
Primary Mentor
Asdis Finnsdottir Wagner
Start Date
3-5-2022 12:45 PM
End Date
3-5-2022 1:00 PM
Presentation Type
Oral Presentation
Description
Watch recording of live presentation
Background: ECMO is rarely utilized in pediatric oncology and bone marrow transplant (BMT) populations due to concerns surrounding poor prognoses and high rates of complications. Patients with malignancies are often not offered ECMO as an option. There is paucity of data to determine whether a pediatric oncology or bone marrow transplant patient is an appropriate candidate for ECMO.
Methods: This is a single center retrospective cohort study on pediatric patients with primary oncologic diagnosis or history of bone marrow transplant who required VA- or VV-ECMO from 2015-2020.
Results: Twelve patients were identified with a 58% survival. Those that did not survive, died prior to decannulation. The most common underlying diagnosis was leukemia/lymphoma (n=8). Six patients had undergone BMT and one had received CAR-T therapy. Sixty seven percent of survivors were still alive at 1 year follow-up. All non-surviving patients had leukemia/lymphoma whereas only 37.5% of surviving patients had leukemia/ lymphoma. There was an age disparity in survival (median of 13.9 years for survivors, 4.4 years for non-survivors). Hemorrhagic/thromboembolic complications, component/circuit change, blood product use and infection were not predictive of mortality.
Conclusions: This single center report offers a unique perspective as it is to our knowledge, the largest single center experience and reports on survival up to one year. Patients surviving decannulation are likely to survive to hospital discharge. Younger patients and those with leukemia/lymphoma had higher mortality. Additionally, complications on ECMO did not suggest higher mortality. Oncology and BMT pediatric patients should not be presumptively excluded from ECMO therapy.
MeSH Keywords
ECMO; Pediatric; oncology; advanced life support
Additional Files
Large single center experience in pediatric oncology and bone marrow transplant patients on ECMO-How should we decide candidacy.pdf (223 kB)Abstract
LargeSingleCenterExperienceinPediatricOncologyandBMTonECMO_Marquess_ChildrensMercy.pptx (5775 kB)
Poster
Included in
Higher Education and Teaching Commons, Medical Education Commons, Pediatrics Commons, Science and Mathematics Education Commons
Large single center experience in pediatric oncology and bone marrow transplant patients on ECMO: How should we decide candidacy?
Watch recording of live presentation
Background: ECMO is rarely utilized in pediatric oncology and bone marrow transplant (BMT) populations due to concerns surrounding poor prognoses and high rates of complications. Patients with malignancies are often not offered ECMO as an option. There is paucity of data to determine whether a pediatric oncology or bone marrow transplant patient is an appropriate candidate for ECMO.
Methods: This is a single center retrospective cohort study on pediatric patients with primary oncologic diagnosis or history of bone marrow transplant who required VA- or VV-ECMO from 2015-2020.
Results: Twelve patients were identified with a 58% survival. Those that did not survive, died prior to decannulation. The most common underlying diagnosis was leukemia/lymphoma (n=8). Six patients had undergone BMT and one had received CAR-T therapy. Sixty seven percent of survivors were still alive at 1 year follow-up. All non-surviving patients had leukemia/lymphoma whereas only 37.5% of surviving patients had leukemia/ lymphoma. There was an age disparity in survival (median of 13.9 years for survivors, 4.4 years for non-survivors). Hemorrhagic/thromboembolic complications, component/circuit change, blood product use and infection were not predictive of mortality.
Conclusions: This single center report offers a unique perspective as it is to our knowledge, the largest single center experience and reports on survival up to one year. Patients surviving decannulation are likely to survive to hospital discharge. Younger patients and those with leukemia/lymphoma had higher mortality. Additionally, complications on ECMO did not suggest higher mortality. Oncology and BMT pediatric patients should not be presumptively excluded from ECMO therapy.
